Related Experiment Video
Updated: May 6, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis
Adolfo Del Canto1, Claudia Cárcamo1, Lorena Garcia1,2
1Departamento de Neurología, Pontificia Universidad Católica de Chile, Santiago, Chile.
Background:
Real-world studies are needed to expand our knowledge concerning populations underrepresented in clinical trials.
Objective:
This study aimed to evaluate the safety and effectiveness of ocrelizumab in Hispanic/Latino people with multiple sclerosis (pwMS).
Methods:
Prospective longitudinal observational study including pwMS who received at least one dose of ocrelizumab between June 2018 and October 2023.
Results:
A total of 305 pwMS (223 relapsing-remitting MS (RRMS), 29 secondary progressive MS (SPMS), and 53 primary progressive MS (PPMS)), 67% female, mean age 38.7, mean disease duration 7 years, and median Expanded Disability Status Scale (EDSS) 2.0 (range 0-7). Median follow-up under ocrelizumab 29.5 (range 6-65) months. Only 1 patient had a relapse, 12-week-confirmed disability worsening was observed in 12.4% of the full cohort. Survival analysis showed higher risk of 12-week-confirmed disability worsening in SPMS compared with RRMS and PPMS (p = 0.0009). Magnetic resonance imaging (MRI) activity was significantly reduced from baseline across all disease phenotypes. Serious infections were observed in 4.6%, and two patients died during follow-up (one serious COVID-19 and one metastatic cancer). Notably, 22 pregnancies were reported, with 11 newborns and 6 pregnancies still on course.
Conclusion:
This study supports the effectiveness of ocrelizumab in a real-world cohort of individuals from traditionally underrepresented groups, such as the Latin American population, with a consistent safety profile in patients receiving care at a specialized MS Unit.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Multiple Sclerosis l: Introduction
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

